Geographic Atrophy (Advanced Dry AMD)

GA management requires a retinal specialist, not just a general ophthalmologist. They will formally document your lesion size, location, and progression rate using OCT imaging.

Your treatment decisions depend on your baseline lesion size and location. Get OCT and fundus photography performed and saved. Document your progression over 6–12 months.

AREDS2 formulation (vitamin C, vitamin E, lutein, zeaxanthin, zinc) is the standard recommendation to prevent progression from intermediate to advanced AMD.

Geographic atrophy (GA) is the advanced stage of dry AMD. Retinal pigment epithelium (RPE) cells in the macula progressively die off, creating expanding areas of retinal atrophy. Central vision loss is gradual but permanent, as photoreceptors above the dead RPE cells also die.

No. Syfovre and Izervay do not restore lost vision. They slow the progression of geographic atrophy — reducing GA lesion growth by ~14–22% compared to sham injection. This is meaningful for preserving remaining vision over years, but patients should understand these are disease-modifying drugs, not vision-restoring drugs.

This is nuanced. Both drugs carry risks of wet AMD conversion (~6–7%) and serious eye infection (rare). The benefit is modest (14–22% growth reduction). The decision should be made with a retinal specialist based on your lesion location, size, and rate of progression.